All In Biotech

Drug Trial Radar · NCT06438757

Trial of JYB1904 in Patients With Allergic Asthma

Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Jun 19, 2024

Primary completion

Nov 20, 2025

Study completion Dec 20, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Jun 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Conditions

  • Allergic Asthma

Interventions

  • JYB1904Drug

    Participants will receive JYB1904 every 8 weeks for 24 weeks.

  • OmalizumabDrug

    Participants will receive Omalizumab every 2/4 weeks for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum concentrations of JYB1904Time frame: Baseline through 337 days post-dose
  2. Serum concentrations of IgETime frame: Baseline through 337 days post-dose
  3. Adverse Events(AEs)Time frame: Baseline through 337 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.